Global Raloxifene Hydrochloride Tablets Market / Sector Research Report 2020-2029 (Includes Business Impact of COVID-19)

                                          
Abstract, Snapshot, Market Analysis & Market Definition: Global Raloxifene Hydrochloride Tablets Market


Introduction to Raloxifene

Raloxifene is a second-generation selective estrogen receptor modulator (SERM) that mediates anti-estrogenic effects on breast and uterine tissues, and estrogenic effects on bone, lipid metabolism, and blood coagulation. Exhibiting tissue-specific effects distinct from estradiol, raloxifene is the first of the benzothiophene group of antiestrogens to be labeled a SERM.

Raloxifene hydrochloride specifically binds to estrogen receptors in responsive tissue, including liver, bone, breast, and endometrium. The resulting ligand-receptor complex is translocated to the nucleus where, depending on the tissue type, it promotes or suppresses the transcription of estrogen-regulated genes, thereby exerting its agonistic or antagonistic effects. This agent functions as an estrogen agonist in lipid metabolism, thereby decreasing total and LDL cholesterol levels. In tissue like bone, it decreases bone resorption and bone turnover and increases bone mineral density. Raloxifene hydrochloride acts as an estrogen antagonist in uterine and breast tissue. This agent also exerts an anti-proliferative effect on estrogen-sensitive breast cancer. The main effects of raloxifene are to preserve bone mineral density and decrease the risk of breast cancer in postmenopausal women. Compared to estrogen and tamoxifen, raloxifene was not associated with an increased risk of uterine cancer and it does not cause endometrial proliferation.

Available in many countries worldwide, raloxifene was initially approved by the FDA in December 1997 under the market name Evista® for the management and prevention of osteoporosis in postmenopausal women and reduction in risk for invasive breast cancer in postmenopausal women with osteoporosis or those who are at high risk for invasive breast cancer.

Due to the off-target actions by HRT, newer non-hormonal agents such as raloxifene and tamoxifen have been developed to reduce adverse events through selective pharmacological actions on tissue-specific therapeutic targets.

In 2020, the market size of Raloxifene Hydrochloride Tablets is xx million US$ and it will reach xx million US$ in 2026, growing at a CAGR of xx% from 2021; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2026, with a CAGR of xx% during the forecast period. In this report, 2020 has been considered as the base year and 2021 to 2026 as the forecast period to estimate the market size for Raloxifene Hydrochloride Tablets.

This report studies the global market size of Raloxifene Hydrochloride Tablets especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia). This study presents the Raloxifene Hydrochloride Tablets sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025. For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

Market Segmentation, Outlook & Viewpoint: Global Raloxifene Hydrochloride Tablets Market

Segmentation by Product Type: Breakdown of data from the year 2015 to 2020 and forecast until 2026 or 2029(as per your requirement):

 	
Original Drugs
 	
Generic Drugs

Segmentation by Application: Breakdown of data from the year 2015 to 2020 and forecast until 2026 or 2029(as per your requirement):

 	
Hospital Pharmacies
 	
Retail Pharmacies
 	
Online Pharmacies

Top Companies & Key Players: Global Raloxifene Hydrochloride Tablets Market

 	
Eli Lilly and Company
 	
Teva Pharmaceutical Industries Ltd.
 	
Amneal Pharmaceuticals
 	
Aurobindo Pharma
 	
Glenmark
 	
Sciegen Pharmaceutical
 	
InvaGen Pharmaceuticals Inc
 	
Jiangsu Hengrui Medicine
 	
TEVA Canada Limited
 	
Pd Rx Pharmaceuticals, Inc.
 	
Lake Erie Medical &Surgical Supply Dba Quality Care Products Llc
 	
Pro Doc Limitee
 	
AvPAK
 	
Cadila Pharmaceuticals Limited
 	
American Health Packaging
 	
Dr.Reddy’s Laboratories Inc
 	
KAISER FOUNDATION HOSPITALS
 	
A-S Medication Solutions
 	
Cipla USA Inc.
 	
Amneal Pharmaceuticals LLC
 	
Actavis Pharma Company
 	
Prasco, Laboratories
 	
Apotex Corporation

Key Insights Covered: Global Raloxifene Hydrochloride Tablets Market
1. North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Raloxifene Hydrochloride Tablets industry.
2. Global major manufacturers' operating situation (sales, revenue, growth rate and gross margin) of Raloxifene Hydrochloride Tablets industry.
3. Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of Raloxifene Hydrochloride Tablets industry.
4. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Raloxifene Hydrochloride Tablets industry.
5. Global market size (sales, revenue) forecast by regions and countries from 2021 to 2026 of Raloxifene Hydrochloride Tablets industry.

Research Methodology: Global Raloxifene Hydrochloride Tablets Market

 	
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
 	
Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
 	
Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among others.